1.Clinical trial of myocardial protection using cold oxygenated diluted blood cardioplegia in child age.
The Korean Journal of Thoracic and Cardiovascular Surgery 1992;25(3):211-219
No abstract available.
Child*
;
Heart Arrest, Induced*
;
Humans
;
Oxygen*
4.A case of clear cell adenocarcinoma of the vagina.
Gum Noh LEE ; Kwan Soo KIM ; Young Hee KIM ; Hyung Ryul LEE ; Dong Kyu JEONG
Korean Journal of Obstetrics and Gynecology 1993;36(7):1033-1038
No abstract available.
Adenocarcinoma, Clear Cell*
;
Vagina*
6.Modified anatomic repair of corrected transposition of the great arteries with ventricular septal defect and pulmonary outflow obstruction.
Kyeh Hyeon PARK ; Jeong Ryul LEE ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phill SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1991;24(11):1149-1153
No abstract available.
Arteries*
;
Heart Septal Defects, Ventricular*
7.Effect of fructose-1, 6-diphosphate(FDP) on red blood cells after extracorporeal circulation.
Jeong Ryul LEE ; Jong Myun HONG ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phill SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1992;25(7):693-701
No abstract available.
Erythrocytes*
;
Extracorporeal Circulation*
8.Expression of EGFR in Non-small Cell Lung Cancer and its Effects on Survival.
Tuberculosis and Respiratory Diseases 1997;44(6):1285-1295
BACKGROUND: EGFR is one of the initial step in signal transduction pathway about multistep carcinogenesis. It is homologous to oncogene erbB-2 and is the receptor for EGF and TGF alpha. EGFR has important role in the growth and differentiation of tumor cells. So, EGFR in non-small cell lung cancer was examined to search for possible evidence as clinical prognostic factor. METHODS: To investigate the role of EGFR in lung cancer, the author performed immunohistochemical stain of EGFR on 57 resected primary non-small cell lung cancer specimens. And the author analyzed the correlation between EGFR expression, clinical parameters, S and G1 phase fraction and survival. RESULTS: 1) EGFR were detected in 56% of total 57 patients (according to histologic type, squamous cancer 50%, adenocarcinoma 63%, large cell cancer 75%) (according to TNM stage, stage I 64%, stage II 38%, stage III 55%) (according to cellular differentiation, well 50%, moderately 52%, poorly 65%). All differences were insignificant. 2) Using the flow cytometric analysis, mean S-phase fraction of EGFR (+) and (-) group were 22.3(+/-10.5)%. 18.0(+/-10.9)% (p>0.05), mean G1-phase fraction of EGFR (+) and (-) group were 68.4(+/-11.6)%, 71.1(+/-12.8)%, (p>0.05) 3) Two-year survival rate of EGFR (+) and (-) group were 53%, 84%, median survival time of EGFR (+) and (-) group were 26, 53 months. (p<0.05, Kaplan-Meier, generalized Wilcox) CONCLUISON: EGFR immunostaining may be a simple and useful method for survival prediction in non-small cell lung cancer.
Adenocarcinoma
;
Carcinogenesis
;
Carcinoma, Non-Small-Cell Lung*
;
Epidermal Growth Factor
;
G1 Phase
;
Humans
;
Lung Neoplasms
;
Oncogenes
;
Signal Transduction
;
Survival Rate
9.Correlation of Proliferating Cell Nuclear Antigen (PCNA) Expression and S-phase Fraction, Survival Rate in Primary Non-Small Cell Lung Cancer.
Sei Hoon YANG ; Hak Ryul KIM ; Ki Seon GU ; Byung Hak JUNG ; Eun Taik JEONG
Tuberculosis and Respiratory Diseases 1997;44(4):756-765
BACKGROUND: To study the prognosis of patients with lung cancer, many investigators have reported the methods to detect cell proliferation in tissues including PCNA, thymidine autoradiography, flow cytometry and Ki-67. PCNA, also known as cyclin, is a cell related nuclear protein with 36KD intranuclear polypeptide that is maximally elevated in S phase of proliferating cells. In this study, PCNA was identified by paraffin-embedding tissue using immunohistochemistry which has an advantage of simplicity and maintenance of tissue architecture. The variation of PCNA expression is known to be related with proliferating fraction, histologic type, anatomic(TNM) stage, degree of cell differentiation, S-phase fraction and survival rate. We analyzed the correlation between PCNA expression and S-phase fraction, survival. METHODS: To investigate expression of PCNA in primary lung cancer, we used immunohistochemical stain to paraffin-embedded sections of 57 resected primary non-small cell lung cancer specimen and the results were analyzed according to the cell type, cell differentiation, TNM stage, S-phase fraction and survival. RESULTS: PCNA expression was dMded into five group according to degree of staging(-, +, ++, +++,++++). Squamous cell type showed high positivity than in adenocarcinoma. Nonsignificant difference related to TNM stage was noticed. Nonsignificant difference related to degree of cell differentiation was noticed. S-phase fraction was increased wit advance of PCNA positivity, but t could not reach the statistic significance. The 2 year survival rate and median survival time were -50% 13 months, +75% 41.3 months, ++73% 33.6 months, +++67% 29.0 months, ++++25% 9 months with statistic significance (P<0.05, Kaplan-Meier, generalized Wilcox). CONCLUSION: From this study. PCNA expression was high positive n squamous cell cancer. And, there was no relationship between PCNA positivity and TNM stage, cellular differentiation or S-phase fraction. But, the patients with high positive PCNA staining showed poor survival rate than the patients with lower positive PCNA. It was concluded that PCNA immunostaining is a simple and useful method for survival prediction in paraffin embedded tissue of non-small cell lung cancer.
Adenocarcinoma
;
Autoradiography
;
Carcinoma, Non-Small-Cell Lung*
;
Cell Differentiation
;
Cell Proliferation
;
Cyclins
;
Flow Cytometry
;
Humans
;
Immunohistochemistry
;
Lung Neoplasms
;
Neoplasms, Squamous Cell
;
Nuclear Proteins
;
Paraffin
;
Prognosis
;
Proliferating Cell Nuclear Antigen*
;
Research Personnel
;
S Phase
;
Survival Rate*
;
Thymidine
10.Surgical treatment of patent ductus arteriosus in preterm and infants with severe heart failure and cardiac cachexia.
Seong Jae LEE ; Jeong Ryul LEE ; Yong Jin KIM ; Joon Ryang RHO ; Kyung Phill SUH
The Korean Journal of Thoracic and Cardiovascular Surgery 1993;26(12):915-919
No abstract available.
Cachexia*
;
Ductus Arteriosus, Patent*
;
Heart Failure*
;
Heart*
;
Humans
;
Infant*